HOME >> BIOLOGY >> NEWS
Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma

Two new studies may lead to the development of more effective therapies for individuals with multiple myeloma (MM), a common and incurable blood cell cancer. The research, published by Cell Press in the August issue of the journal Cancer Cell, provides new insight into the molecular mechanisms that underlie aberrant NF-κB activity in MM tumor cells and underscores the relevance of the NF-κB signaling pathway as a target for MM therapy.

MM is a cancer of the plasma cell, a blood cell that produces antibodies to help the body fight off infections. Previous research implicates abnormal activation of the NF-κB signaling pathway as a key event in MM pathology. NF-κB target genes are known to be involved in cell proliferation and cell survival. Although there is significant overlap and interplay between them, there are two separate pathways that lead to activation of NF-κB, the classical pathway and the alternative pathway.

Constitutive activation of NF-κB to block apoptosis has been implicated in various types of cancer, but the molecular mechanisms involved are not well understood. Two separate research groups used a variety of sophisticated genomic techniques to examine mutations in hundreds of MM patient samples and cell lines to identify mutations that impact NF-κB activation.

Dr. Louis M. Staudt from the National Cancer Institute led a research group who revealed the importance of both the classical and alternative NF-κB pathways in MM pathogenesis. Most MM patient samples examined exhibited NF-κB pathway activation via diverse genetic abnormalities. Importantly, targeted disruption of the classical NF-κB signaling blocked myeloma proliferation and induced cell death. These genetic and functional data provide a molecular framework for the rational development of NF-κB pathway inhibitors for the therapy of MM, offers Dr. Staudt.

In a separate study, Dr. Rafael Fonseca, f
'"/>

Contact: Erin Doonan
edoonan@cell.com
617-397-2802
Cell Press
13-Aug-2007


Page: 1 2

Related biology news :

1. Diverse sea bugs revealed on landmark Atlantic cruise to census zooplankton
2. Diverse tropical forests defy metabolic ecology models
3. Does the desire to consume alcohol and tobacco come from our genetic makeup?
4. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
5. Penn researchers discover pathway that eliminates genetic defects in red blood cells
6. Identifying the mechanism behind a genetic susceptibility to type 2 diabetes
7. After a decades-long search, scientists identify new genetic risk factors for multiple sclerosis
8. Discoverer of Sly Syndrome finds way of delivering medicine to fight rare genetic disorder
9. Identified main genetic variants involved in response to HIV
10. Restless legs genetics on the move
11. UK scientists lift lid on genetics of coronary artery disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... (PRWEB) , ... August 25, ... ... clinical-stage biotechnology company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex ... enrolment in its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, Inc., a ... U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug ... of severe COVID-19. Approval of this IND allows Sentien to initiate a Phase ...
(Date:8/12/2020)... SOUTHFIELD, Mich. (PRWEB) , ... August 11, 2020 ... ... Janssen R&D subsidiary based in Princeton, NJ, have entered into license agreements with ... discovery and development. Both Roche and J&J have annual Research and Development ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... 11, 2020 , ... The FSHD Society announced today that ... Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on funding of ... academic research centers in the United States and Europe with expertise in FSHD ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a highly regarded CDMO ... the purchase of greenfield for a new, expanded manufacturing facility. The site is ... in the initial acquisition, with an option to purchase an additional 21 acres ...
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive ... patients may choose which extremities they would like treated. , Several studies have shown ... At R3 International, umbilical cord tissue is obtained from a lab with a long ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... can combine up to three different materials for use with CRM, neurostimulation, vascular, ... to three materials to meet specific design requirements, performance, and cost criteria; especially ...
Breaking Biology Technology:
Cached News: